NCT00829647View on ClinicalTrials.gov

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

March 1, 2016

Conditions
Chronic Lymphocytic LeukemiaLeukemia
Interventions
DRUG

dasatinib and lenalidomide

dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Celgene Corporation

INDUSTRY

lead

Scripps Health

OTHER